دورية أكاديمية
Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib
| العنوان: | Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib |
|---|---|
| المؤلفون: | Legros, L., Guilhot, J., Huault, S., Mahon, F.X., Preudhomme, C., Guilhot, F., Hueber, A.O. |
| المساهمون: | Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UniCA), INSERM CIC 0802 (INSERM - CHU de Poitiers), Université de Poitiers = University of Poitiers (UP)-Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie )-Institut National de la Santé et de la Recherche Médicale (INSERM), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Bergonié Bordeaux, UNICANCER, Institut pour la Recherche sur le Cancer de Lille (U837 INSERM - IRCL), Institut pour la recherche sur le cancer de Lille Lille (IRCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille) |
| المصدر: | ISSN: 0145-2126. |
| بيانات النشر: | HAL CCSD Elsevier |
| سنة النشر: | 2014 |
| المجموعة: | HAL Université Côte d'Azur |
| مصطلحات موضوعية: | Angiogenesis, Chronic myeloid leukemia (CML), Imatinib, Interferon-alpha, Vascular Endothelial Growth Factor (VEGF), [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; In chronic myeloid leukemia (CML), evidence is supporting the role of VEGF in growth, and survival of leukemia cells. The evaluation of plasma VEGF levels in 403 CML patients randomized within SPIRIT study to received imatinib-400mg versus imatinib+cytarabine versus imatinib+interferon (IFN) versus imatinib-600mg demonstrated that VEGF is an independent factor of BCR-ABL burden. VEGF low levels at diagnosis were associated with a progression-free survival of 100% at 48 months. Under treatment, significant lowest levels were observed in imatinib+IFN arm. These results support the use of VEGF as a parameter to predict CML evolution and let us to speculate about antiangiogenic properties of IFN. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/24553365; inserm-03360989; https://inserm.hal.science/inserm-03360989Test; https://inserm.hal.science/inserm-03360989/documentTest; https://inserm.hal.science/inserm-03360989/file/1-s2.0-S0145212614000289-main.pdfTest; PUBMED: 24553365 |
| DOI: | 10.1016/j.leukres.2014.01.010 |
| الإتاحة: | https://doi.org/10.1016/j.leukres.2014.01.010Test https://inserm.hal.science/inserm-03360989Test https://inserm.hal.science/inserm-03360989/documentTest https://inserm.hal.science/inserm-03360989/file/1-s2.0-S0145212614000289-main.pdfTest |
| رقم الانضمام: | edsbas.43F6443B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.leukres.2014.01.010 |
|---|